Analyst Downgrades – NASDAQ:CLDX – Celldex Therapeutics (NASDAQ:CLDX) Stock Gets Downgraded By Cantor Fitzgerald from Overweight to Neutral

ME Staff
-
0

Analyst Ratings For NASDAQ:CLDX – Celldex Therapeutics (NASDAQ:CLDX)

Today, NASDAQ:CLDX – Celldex Therapeutics (NASDAQ:CLDX) stock was downgraded by Cantor Fitzgerald from Overweight to Neutral with a price target of $3.00.

Some recent analyst ratings include

  • 4/17/2018-Cantor Fitzgerald was Downgraded by analysts at Cantor Fitzgerald from a “Overweight ” rating to a ” Neutral” rating. They now have a $3.00 price target on the stock.
  • 4/16/2018-Cowen was Downgraded by analysts at Cowen from a “Outperform ” rating to a ” Market Perform” rating.
  • 3/8/2018-Leerink Swann Reiterated Rating of Market Perform .
  • 12/6/2017-WBB Securities Reiterated Rating of Buy.
  • 6/29/2017-Aegis Reiterated Rating of Buy.
  • 5/11/2017-Jefferies Group Reiterated Rating of Hold.

Recent Insider Trading Activity For NASDAQ:CLDX – Celldex Therapeutics (NASDAQ:CLDX)
NASDAQ:CLDX – Celldex Therapeutics (NASDAQ:CLDX) has insider ownership of 4.10% and institutional ownership of 55.49%.

  • On 9/2/2016 Tibor Keler, VP, bought 3,000 with an average share price of $3.32 per share and the total transaction amounting to $9,960.00.
  • On 11/23/2015 Avery W. Catlin, CFO, sold 25,000 with an average share price of $18.00 per share and the total transaction amounting to $450,000.00.
  • On 8/25/2015 Larry Ellberger, Director, bought 5,000 with an average share price of $14.00 per share and the total transaction amounting to $70,000.00.
  • On 8/20/2015 Larry Ellberger, Director, bought 5,000 with an average share price of $15.00 per share and the total transaction amounting to $75,000.00.
  • On 8/18/2015 Larry Ellberger, Director, bought 5,000 with an average share price of $15.95 per share and the total transaction amounting to $79,750.00.
  • On 8/13/2015 Anthony S Marucci, CEO, bought 5,800 with an average share price of $16.81 per share and the total transaction amounting to $97,498.00.
  • On 8/13/2015 Larry Ellberger, Director, bought 5,000 with an average share price of $16.59 per share and the total transaction amounting to $82,950.00.

Recent Trading Activity for NASDAQ:CLDX – Celldex Therapeutics (NASDAQ:CLDX)
Shares of NASDAQ:CLDX – Celldex Therapeutics closed the previous trading session at 0.88 up +0.12 15.24% with 0.800000011920929 shares trading hands.